CoChat

Microsatellite instability-low colorectal cancer acquires a KRAS mutation during the progression from Dukes' A to Dukes' B

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Abstract

The classification of colorectal cancer (CRC) by microsatellite instability (MSI) status is important for effective clinical management. In fact, microsatellite instability-high (MSI-H) cancer has distinctive clinicopathological and molecular features. However, microsatellite instability-low (MSI-L) cancer is not clearly defined. The objective of this study was to further clarify the characteristics of MSI-L CRC. A consecutive series of 940 primary CRCs were subdivided into three groups according to the level of MSI and analyzed the clinicopathological features and genetic changes in the KRAS, BRAF and p53 mutation and the loss of heterozygosity (LOH) of adenomatous polyposis coli (APC) gene and methylation status of the O(6)-methylguanine-DNA methyltransferase (MGMT) and MLH1 promoter. Of the 940 CRCs, 5.9% were MSI-H, 7.1% were MSI-L and 87% were microsatellite stable (MSS). KRAS and BRAF mutations were detected in 39.4 and 4.6% of the CRCs, respectively. The frequency of KRAS mutations in MSI-H, MSI-L and MSS cancer was 30, 48 and 39%, respectively. The proportion of KRAS mutations in MSI-L cancer increased from 16 to 63% accompanying the progression from Dukes' A to Dukes' B. While the LOH of D5S346, which is located near the APC gene, and p53 mutation was observed in 75 and 67% of MSI-L CRC at Dukes' A, respectively. These results indicated that the LOH of APC and p53 mutation has already occurred by the Dukes' A lake 'suppressor pathway' but not the KRAS mutation in MSI-L CRCs. The genes involving MSI-L carcinogenesis are similar to MSS but the timing and frequency of the KRAS mutation is different.

Overview

Integrity signals

Registry

Crossref · 10.1093/carcin/bgp017

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 14

  1. Boland, 1998, Cancer Research, 58, 5248
  2. Risio, 1996, Cancer Research, 56, 5470
  3. Cunningham, 1998, Cancer Research, 58, 3455
  4. Halford, 2002, Cancer Research, 62, 53
  5. Dietmaier, 1997, Cancer Research, 57, 4749
  6. Parc, 2000, Cancer Research, 60, 2225
  7. Laiho, 2002, Cancer Research, 62, 1166
  8. Kambara, 2001, Cancer Research, 61, 7743
  9. Esteller, 2000, Cancer Research, 60, 2368
  10. 1996, 111, 307
  11. Hamelin, 1993, Oncogene, 8, 2213
  12. 2000, 119, 323
  13. Esteller, 2001, Cancer Research, 61, 4689
  14. 1993, 104, 1044

Cited by

See all 76

Metadata

Authors
Asaka, S.-I., Arai, Y., Nishimura, Y., Yamaguchi, K., Ishikubo, T., Yatsuoka, T., Tanaka, Y., & Akagi, K.
Affiliations
Saitama Cancer Center (JP)
Corresponding author
Akagi, K.
Venue
Carcinogenesis
Published
2009-01-09
Volume
30
Issue
3
Pages
494-499
ISSN
  • 0143-3334 (ISSN-L)
  • 1460-2180
OpenAlex
W2140416445
Cited by
76
References
52
Citations by year
2026: 4 · 2025: 3 · 2024: 3 · 2023: 2 · 2022: 5 · 2021: 8 · 2020: 7 · 2019: 7 · 2018: 7 · 2017: 3 · 2016: 8 · 2015: 5 · 2014: 5 · 2013: 1 · 2012: 2
FWCI
1.88
Type
journal article
Language
en
Open access
closed
Locations
  • Carcinogenesis (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Keywords
KRAS mutation, colorectal cancer progression, BRAF mutation, TP53 mutation, MGMT promoter methylation, MLH1 promoter methylation, tumor suppressor pathways, microsatellite instability-high, microsatellite stable colorectal cancer
MeSH terms
MutL Protein Homolog 1, Heterozygote, Humans, Mutation, Nuclear Proteins, Promoter Regions, Genetic, Proto-Oncogene Proteins, Colorectal Neoplasms, Tumor Suppressor Protein p53, Proto-Oncogene Proteins p21(ras), ras Proteins, Loss of Heterozygosity, O(6)-Methylguanine-DNA Methyltransferase, Proto-Oncogene Proteins B-raf, Adaptor Proteins, Signal Transducing, Microsatellite Instability

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.